Position in NGEN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,396,680
New position
Shares Held
678,000
first reported quarter
Ownership
0.631%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#5
of 62 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARMISTICE CAPITAL, LLC holds $1,506,954,940 across 50 Biotechnology names. NGEN ranks #40 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
288,000 | $154,641,600 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,201,342 | $102,342,324 | |
| 3 | INCY |
Incyte Corp
|
900,005 | $102,024,566 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
1,572,539 | $89,335,940 | |
| 5 | AGIO |
Agios Pharmaceuticals, Inc.
|
2,400,000 | $89,064,000 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
1,071,395 | $87,393,690 | |
| 7 | DYN |
Dyne Therapeutics, Inc.
|
3,087,226 | $68,567,289 | |
| 8 | IMVT |
Immunovant, Inc.
|
1,736,000 | $66,888,080 |
All Filings in NGEN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,396,680 | 678,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||